Global Research Status and Trends of Interactions Between Traditional Chinese Medicine and Pulmonary Fibrosis: A New Dawn in Treatment

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Aug 16

PMID 39149021

Authors

Bokai Wei

Haozheng Li

Chengyu Wang

Jing Hu

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary fibrosis (PF) remains a major sequela of COVID-19, yet its pharmacotherapy remains unsatisfactory. Recently, Traditional Chinese medicine (TCM) has garnered increasing recognition among patients and researchers because of its few side effects and efficacy. The objective of this study is to use bibliometric analysis to explore the current research landscape and emerging trajectories of TCM treating PF(TCM/PF) researches, and comprehensively evaluate publications with substantial citations within the domain of TCM/PF.

Materials And Methods: TCM/PF publications from 1996 to June 15, 2023 were identified by a comprehensive search of the Web of Science Core Collection (WoSCC). The Bibliometrix of Origin, CiteSpace, Gephi, dycharts and VOSviewer were used for bibliometric analysis.

Results: A total of 358 papers were included. A rapid increase in the number of papers after 2013 was observed. China had the highest publication output and research contributions in this field. Beijing University of Traditional Chinese Medicine and Nanjing University of Traditional Chinese Medicineare leaders in productive research of this field. Nanjing University of Traditional Chinese Medicine had the highest citations (227). LI JIANSHENG from Henan University of Chinese Medicine was the most prolific author (8), with the highest number of citations (61), and TONG XIAO LIN from China Academy of Chinese Medical Sciences had the highest H-index (30). The leading journal publishing the most research (37) is Frontiers in Pharmacology and the Journal of Ethnopharmacology had the highest total citations (486). Burst analysis of keywords revealed three distinct phases of research. 1996 to 2013 marked the nascent stage of TCM/PF research; from 2014 to 2018, studies gradually focused on the underlying mechanisms governing TCM/PF. The most significant phase occurred from 2019 onward, where TCM/PF exhibited an explosive growth trend. This progression signifies a transition from foundational explorations to a comprehensive understanding of the mechanisms involved, ultimately leading to the current surge in research activities focused on TCM/PF. Notable research teams of this stage, led by LI JIAN SHENG and TONG XIAO LIN, have been at the forefront of advancing TCM/PF research. Their studies on Jinshui Huanxian formula and Qimai Feiluoping decoction have been pivotal in advancing the frontier of research in this domain. Furthermore, the monomeric compounds, including emodin, curcumin, salvianolic acid, baicalin, and oxymatrine, have sustained longstanding prominence.

Conclusions: This study gained insight into the research status, focal areas and evolving trends of global TCM/PF research. It also identified the most cited articles in TCM/PF and analyzed their characteristics, which may hold significant relevance for both clinical researchers and practitioners on future directions in this field.

Citing Articles

Comparative Pharmacokinetic Assessment of Curcumin in Rats Following Intratracheal Instillation Versus Oral Administration: Concurrent Detection of Curcumin and Its Conjugates in Plasma by LC-MS/MS.

Li N, Lou J, Wang L, Zhang W, Jin C, Zhuang X Pharmaceutics. 2024; 16(11).

PMID: 39598582 PMC: 11597260. DOI: 10.3390/pharmaceutics16111459.

References

Li M, Li Y, Li J, Zhao P, Bai Y, Feng S . Long-Term Effects of TCM Yangqing Kangxian Formula on Bleomycin-Induced Pulmonary Fibrosis in Rats via Regulating Nuclear Factor-B Signaling. Evid Based Complement Alternat Med. 2018; 2017:2089027. PMC: 5745787. DOI: 10.1155/2017/2089027. View

Zhang M, Cao S, Zhang R, Jin J, Zhu Y . The inhibitory effect of salvianolic acid B on TGF-β1-induced proliferation and differentiation in lung fibroblasts. Exp Lung Res. 2014; 40(4):172-85. DOI: 10.3109/01902148.2014.895070. View

Chanda D, Otoupalova E, Smith S, Volckaert T, De Langhe S, Thannickal V . Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2018; 65:56-69. PMC: 6374163. DOI: 10.1016/j.mam.2018.08.004. View

Wang Q, Li W, Hu H, Lu X, Qin S . Monomeric compounds from traditional Chinese medicine: New hopes for drug discovery in pulmonary fibrosis. Biomed Pharmacother. 2023; 159:114226. DOI: 10.1016/j.biopha.2023.114226. View

Wang J, Chen Y, Zhai X, Chu Y, Liu X, Ma X . Visualizing Research Trends and Identifying Hotspots of Traditional Chinese Medicine (TCM) Nursing Technology for Insomnia: A 18-Years Bibliometric Analysis of Web of Science Core Collection. Front Neurol. 2022; 13:816031. PMC: 9009417. DOI: 10.3389/fneur.2022.816031. View

Yang J, Jiang G, Ni K, Fan L, Tong W, Yang J . Emodin inhibiting epithelial-mesenchymal transition in pulmonary fibrosis through the c-MYC/miR-182-5p/ZEB2 axis. Phytother Res. 2022; 37(3):926-934. DOI: 10.1002/ptr.7680. View

Zhou M, Zhang H, Li F, Yu Z, Yuan C, Oliver B . Pulmonary Daoyin as a traditional Chinese medicine rehabilitation programme for patients with IPF: A randomized controlled trial. Respirology. 2020; 26(4):360-369. PMC: 8048896. DOI: 10.1111/resp.13972. View

Liu C . Inhibition of mechanical stress-induced hypertrophic scar inflammation by emodin. Mol Med Rep. 2015; 11(6):4087-92. PMC: 4394962. DOI: 10.3892/mmr.2015.3265. View

Geng Y, Li L, Yan J, Liu K, Yang A, Zhang L . PEAR1 regulates expansion of activated fibroblasts and deposition of extracellular matrix in pulmonary fibrosis. Nat Commun. 2022; 13(1):7114. PMC: 9675736. DOI: 10.1038/s41467-022-34870-w. View

10.

Yang F, Hou R, Liu X, Tian Y, Bai Y, Li J . Yangqing Chenfei formula attenuates silica-induced pulmonary fibrosis by suppressing activation of fibroblast via regulating PI3K/AKT, JAK/STAT, and Wnt signaling pathway. Phytomedicine. 2022; 110:154622. DOI: 10.1016/j.phymed.2022.154622. View

11.

Wang Q, Shi G, Zhang Y, Lu F, Xie D, Wen C . Deciphering the Potential Pharmaceutical Mechanism of GUI-ZHI-FU-LING-WAN on Systemic Sclerosis based on Systems Biology Approaches. Sci Rep. 2019; 9(1):355. PMC: 6344516. DOI: 10.1038/s41598-018-36314-2. View

12.

Liu T, Xu P, Qi S, Ke S, Hu Q, Zhao P . Network Pharmacology-Based Mechanistic Investigation of Jinshui Huanxian Formula Acting on Idiopathic Pulmonary Fibrosis. Evid Based Complement Alternat Med. 2021; 2021:8634705. PMC: 8279870. DOI: 10.1155/2021/8634705. View

13.

De Paula C, Nagashima S, Liberalesso V, Collete M, Silva F, Oricil A . COVID-19: Immunohistochemical Analysis of TGF-β Signaling Pathways in Pulmonary Fibrosis. Int J Mol Sci. 2022; 23(1). PMC: 8745764. DOI: 10.3390/ijms23010168. View

14.

Kang H, Kim Y, Lee C, Lee J, Choi I, Pyun K . Anti-inflammatory effects of Stephania tetrandra S. Moore on interleukin-6 production and experimental inflammatory disease models. Mediators Inflamm. 1996; 5(4):280-91. PMC: 2365809. DOI: 10.1155/S0962935196000415. View

15.

Lin C, Liou C, Chiang C, Huang W, Huang W . Danggui Buxue Tang attenuates eosinophil infiltration and airway hyperresponsiveness in asthmatic mice. Ann Allergy Asthma Immunol. 2011; 107(6):501-9. DOI: 10.1016/j.anai.2011.08.006. View

16.

Guzel A, Kanter M, Aksu B, Basaran U, Yalcin O, Guzel A . Preventive effects of curcumin on different aspiration material-induced lung injury in rats. Pediatr Surg Int. 2008; 25(1):83-92. DOI: 10.1007/s00383-008-2282-x. View

17.

Zhao H, Li C, Li L, Liu J, Gao Y, Mu K . Baicalin alleviates bleomycin‑induced pulmonary fibrosis and fibroblast proliferation in rats via the PI3K/AKT signaling pathway. Mol Med Rep. 2020; 21(6):2321-2334. PMC: 7185294. DOI: 10.3892/mmr.2020.11046. View

18.

Yu Y, Sun Z, Shi L, Zhang Y, Zhou Z, Zhang S . Effects of Feiwei granules in the treatment of idiopathic pulmonary fibrosis: a randomized and placebo-controlled trial. J Tradit Chin Med. 2017; 36(4):427-33. DOI: 10.1016/s0254-6272(16)30058-9. View

19.

Jiang L, Li Y, Yu J, Wang J, Ju J, Dai J . A dry powder inhalable formulation of salvianolic acids for the treatment of pulmonary fibrosis: safety, lung deposition, and pharmacokinetic study. Drug Deliv Transl Res. 2020; 11(5):1958-1968. DOI: 10.1007/s13346-020-00857-7. View

20.

Zhang Y, Lu P, Qin H, Zhang Y, Sun X, Song X . Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potential. Biomed Pharmacother. 2020; 133:111072. PMC: 7836923. DOI: 10.1016/j.biopha.2020.111072. View